Epigenetics: On-Off Switch
Originally presented at HOPA's 14th Annual Conference, March 2018.
In this session we will review the molecular mechanisms of epigenetic drug therapy in malignancy and apply this knowledge to use of these drugs, comprehension of novel drugs in this category, and management of patients receiving these therapies. Given that most clinical successes of epigenetic drugs have occurred in the treatment of hematologic malignancies, they will be the primary focus. The intent is not to provide an exhaustive review of epigenetic drugs but to detail the mechanisms and discuss key examples to provide a framework for understanding this unique drug class. This session is intended for both new and advanced pharmacy practitioners.
Joshua Pecoraro, PharmD BCOP
Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 22, 2021.
This activity has been approved for .1 CEU
This course is also included as part of the Best of 2018 Annual Conference Recordings Bundle.
Release Date: September 26, 2018
Expiration Date: March 22, 2021